The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE).
 
Yasutoshi Kuboki
No Relationships to Disclose
 
Tomohiro Nishina
Speakers' Bureau - Chugai Pharma; Taiho Pharmaceutical
 
Eiji Shinozaki
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
 
Kentaro Yamazaki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Merck; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan (Inst)
 
Kohei Shitara
Honoraria - Chugai Pharma; Takeda
Consulting or Advisory Role - Bayer; Chugai Pharma; Lilly Japan
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Wataru Okamoto
No Relationships to Disclose
 
Takeshi Kajiwara
No Relationships to Disclose
 
Toshihiko Matsumoto
No Relationships to Disclose
 
Takahiro Tsushima
No Relationships to Disclose
 
Nobuo Mochizuki
No Relationships to Disclose
 
Miki Fukutani
No Relationships to Disclose
 
Masako Nakamoto
No Relationships to Disclose
 
Hiromi Hasegawa
No Relationships to Disclose
 
Ayako Sugama
No Relationships to Disclose
 
Shogo Nomura
Employment - Asahi Kasei (I)
 
Akihiro Sato
Honoraria - Dainippon Sumitomo Pharma; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Eisai (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Atsushi Ohtsu
Employment - Celgene (I)
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Merck Serono; Taiho Pharmaceutical
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Takeda
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)